Steadfast and tenacious in our search for transformative therapies TARA-002 TARA-002 is the Company’s lead investigational cell therapy based on the broad immunopotentiator OK-432, which is approved in Japan and Taiwan for lymphatic malformations and multiple oncologic indications. IV Choline Ch ...
Location: United States, Massachusetts, Waltham
Founded date: 2017
Investors 3
| Date | Name | Website |
| 14.08.2020 | Abingworth... | abingworth... |
| 16.09.2024 | Catalio Ca... | cataliocap... |
| - | TVM Capita... | tvm-lifesc... |
Mentions in press and media 3
| Date | Title | Description |
| 11.12.2024 | Protara Announces Closing of $100 Million Public Offering | NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the closing of its underwritt... |
| 13.03.2024 | Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - |
| 03.11.2022 | Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview | /EIN News/ -- - Dose Escalation Ongoing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Following Recent Feedback from the U.S. Food and Drug Administration, Phase 2 Study of TARA-002 in L... |